Abstract
Processing of cancer-associated precursor proteins such as growth factors by the Proprotein Convertase furin is an important cellular process for acquisition of malignant phenotype and metastatic potential of tumor cells. Furin is inhibited by its own prodomain protein which also plays role in the folding of mature furin. Herein, the complete 83-mer furin prodomain protein was chemically synthesized for the first time by solid phase peptide chemistry and its effects on furin activity and tumor cells malignant phenotypes were evaluated. It inhibited furin activity in a competitive manner with low nanomolar inhibition constant (Ki). Expression of furin prodomain cDNA in tumor cells or cells incubated with the corresponding protein blocked furin-cleavage of proPDGF-A. This was associated with significant reduction in tumor cells proliferation, migration as well as invasion. Interestingly shorter synthetic furin prodomain peptides derived from either its primary or secondary activation site alone weakly inhibited furin and displayed limited effects on tumor cells. This suggests that the combined presence of the above two prodomain segments is crucial for prodomains potent furin-inhibitory and hence anticancer activities.
Keywords: Proprotein convertases, furin inhibitor, prodomain, growth factor precursor processing, anticancer activity, invasion, proliferation, migration
Current Medicinal Chemistry
Title: Blockade of Furin Activity and Furin-Induced Tumor Cells Malignant Phenotypes By The Chemically Synthesized Human Furin Prodomain
Volume: 17 Issue: 21
Author(s): A. Basak, A. Chen, N. Scamuffa, D. Mohottalage, S. Basak and A.-M. Khatib
Affiliation:
Keywords: Proprotein convertases, furin inhibitor, prodomain, growth factor precursor processing, anticancer activity, invasion, proliferation, migration
Abstract: Processing of cancer-associated precursor proteins such as growth factors by the Proprotein Convertase furin is an important cellular process for acquisition of malignant phenotype and metastatic potential of tumor cells. Furin is inhibited by its own prodomain protein which also plays role in the folding of mature furin. Herein, the complete 83-mer furin prodomain protein was chemically synthesized for the first time by solid phase peptide chemistry and its effects on furin activity and tumor cells malignant phenotypes were evaluated. It inhibited furin activity in a competitive manner with low nanomolar inhibition constant (Ki). Expression of furin prodomain cDNA in tumor cells or cells incubated with the corresponding protein blocked furin-cleavage of proPDGF-A. This was associated with significant reduction in tumor cells proliferation, migration as well as invasion. Interestingly shorter synthetic furin prodomain peptides derived from either its primary or secondary activation site alone weakly inhibited furin and displayed limited effects on tumor cells. This suggests that the combined presence of the above two prodomain segments is crucial for prodomains potent furin-inhibitory and hence anticancer activities.
Export Options
About this article
Cite this article as:
Basak A., Chen A., Scamuffa N., Mohottalage D., Basak S. and Khatib A.-M., Blockade of Furin Activity and Furin-Induced Tumor Cells Malignant Phenotypes By The Chemically Synthesized Human Furin Prodomain, Current Medicinal Chemistry 2010; 17 (21) . https://dx.doi.org/10.2174/092986710791331040
DOI https://dx.doi.org/10.2174/092986710791331040 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound
Current Cancer Drug Targets Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology Mesenchymal Stem Cells in the Umbilical Cord: Phenotypic Characterization, Secretome and Applications in Central Nervous System Regenerative Medicine
Current Stem Cell Research & Therapy Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas
Current Gene Therapy Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Patent Selections:
Current Biomarkers (Discontinued) Approaches to Improve Cellular Retention of Radiohalogen Labels Delivered by Internalising Tumour-Targeting Proteins and Peptides
Current Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy
Central Nervous System Agents in Medicinal Chemistry Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the TGF-β Superfamily and their Clinical Applications
Mini-Reviews in Medicinal Chemistry Bone Regeneration and Repair
Current Stem Cell Research & Therapy Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design